A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer: ParvOryx02 protocol

A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer: ParvOryx02 protocol

Abstract Background Metastatic pancreatic cancer has a dismal prognosis, with a mean six-month progression-free survival of approximately 50% and a median survival of about 11 months. Despite intensive research, only slight improvements of clinical outcome could be achieved over the last decades. He...

Full description

Bibliographic Details
Main Authors: Jacek Hajda, Monika Lehmann, Ottheinz Krebs, Meinhard Kieser, Karsten Geletneky, Dirk Jäger, Michael Dahm, Bernard Huber, Tilman Schöning, Oliver Sedlaczek, Albrecht Stenzinger, Niels Halama, Volker Daniel, Barbara Leuchs, Assia Angelova, Jean Rommelaere, Christine E. Engeland, Christoph Springfeld, Guy Ungerechts
Format: Article
Language:English
Published: BMC 2017-08-01
Series:BMC Cancer
Subjects:
H-1 parvovirus
Parvovirus
Oncolytic virotherapy
Pancreatic cancer
Pancreatic ductal adenocarcinoma
PDAC
Online Access:http://link.springer.com/article/10.1186/s12885-017-3604-y

Internet

http://link.springer.com/article/10.1186/s12885-017-3604-y

Similar Items